Product Description
biphasic insulin aspart 30/70
Mechanisms of Action: INSR Binder
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BIASP-4343 | N/A |
Completed |
Type 2 Diabetes |
2018-07-04 |
|
| NCT01889095 | P4 |
Completed |
Type 2 Diabetes |
2011-08-01 |
|
| JapicCTI-101139 | P3 |
Completed |
Type 2 Diabetes |
None |